Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419515 | 1.00 | SCN9A (0.36) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL4566138 | 1.00 | SCN9A (0.36) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL20492529 | 0.98 | SCN9A (0.35) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL14135102 | 0.95 | SCN9A (0.33) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL28120063 | 0.95 | SCN9A (0.33) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL248747 | 0.86 | NOS2 (0.39) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL40093 | 0.86 | NOS2 (0.39) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL248746 | 0.86 | NOS2 (0.39) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL632759 | 0.85 | SCN9A (0.35) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| Hydrochloric Acid SCHEMBL661790 | 0.84 | NOS2 (0.38) | SCN9ASCN3ASCN5ADPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718582-B2 | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-08-08 | — | — | US | claimed |
| EP-3820842-B1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | Rottapharm Biotech Srl (IT) | 2023-03-29 | — | — | EP | claimed |
| EP-3820842-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | Rottapharm Biotech S.r.l. (IT) | 2021-05-19 | — | — | EP | claimed |
| US-20210130290-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-05-06 | — | — | US | claimed |
| CN-112638871-A | (R) -4- (1- (1- (4- (trifluoromethyl) benzyl) pyrrolidine-2-carboxamide) cyclopropyl) benzoic acid as EP4 receptor antagonists | 罗达制药生物技术有限责任公司 | 2021-04-09 | — | — | CN | claimed |
| WO-2020012305-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | ROTTAPHARM BIOTECH S.R.L. (IT) | 2020-01-16 | — | — | WO | claimed |
| EP-4565562-B1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026103887-A1 | PROLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 北京康辰药业股份有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2026042018-A1 | 4-{4-[(1-{[4-(PROPAN-2-YL)PHENYL]CARBAMOYL)-D-PROLYL)AMINO]CYCLOHEXYL}BENZOIC ACID DERIVATIVES AS GIPR ANTAGONISTS FOR THE TREATMENT OF DIABETES | PFIZER INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| US-5629406-A | AMINO ACID DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1997-05-13 | — | — | US | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5158970-A | Prolylendopeplidase inhibitors; antiamnesia | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1992-10-27 | — | — | US | disclosed |
| EP-0384341-A2 | New proline derivatives | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4576749-A | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones | E. R. SQUIBB & SONS, INC. (US) | 1986-03-18 | — | — | US | disclosed |
| EP-0138407-A1 | Azetidinones | E.R. Squibb & Sons, Inc. (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718582-B2 | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist | PTGER4, PTGER1, PTGER2 | SCN9A 2392/4885SCN3A 1121/4885SCN5A 1169/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | SCN9A 717/4885SCN3A 627/4885SCN5A 1476/4885 |
| US-20210130290-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | PTGER4, PTGER1, PTGER2 | SCN9A 2392/4885SCN3A 1121/4885SCN5A 1169/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | SCN9A 1588/4885SCN3A 1191/4885SCN5A 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.